2024-09-012025-08-312025-08-31false14284456Molecule Pharma Limited2026-08-31falseiso4217:GBPxbrli:pure142844562024-08-31142844562025-08-31142844562024-09-012025-08-31142844562023-08-31142844562024-08-31142844562023-09-012024-08-3114284456bus:SmallEntities2024-09-012025-08-3114284456bus:AuditExempt-NoAccountantsReport2024-09-012025-08-3114284456bus:FullAccounts2024-09-012025-08-3114284456bus:PrivateLimitedCompanyLtd2024-09-012025-08-3114284456core:WithinOneYear2025-08-3114284456core:AfterOneYear2025-08-3114284456core:WithinOneYear2024-08-3114284456core:AfterOneYear2024-08-3114284456core:ShareCapital2025-08-3114284456core:SharePremium2025-08-3114284456core:RevaluationReserve2025-08-3114284456core:OtherReservesSubtotal2025-08-3114284456core:RetainedEarningsAccumulatedLosses2025-08-3114284456core:ShareCapital2024-08-3114284456core:SharePremium2024-08-3114284456core:RevaluationReserve2024-08-3114284456core:OtherReservesSubtotal2024-08-3114284456core:RetainedEarningsAccumulatedLosses2024-08-3114284456core:LandBuildings2025-08-3114284456core:PlantMachinery2025-08-3114284456core:Vehicles2025-08-3114284456core:FurnitureFittings2025-08-3114284456core:OfficeEquipment2025-08-3114284456core:NetGoodwill2025-08-3114284456core:IntangibleAssetsOtherThanGoodwill2025-08-3114284456core:ListedExchangeTraded2025-08-3114284456core:UnlistedNon-exchangeTraded2025-08-3114284456core:LandBuildings2024-08-3114284456core:PlantMachinery2024-08-3114284456core:Vehicles2024-08-3114284456core:FurnitureFittings2024-08-3114284456core:OfficeEquipment2024-08-3114284456core:NetGoodwill2024-08-3114284456core:IntangibleAssetsOtherThanGoodwill2024-08-3114284456core:ListedExchangeTraded2024-08-3114284456core:UnlistedNon-exchangeTraded2024-08-3114284456core:LandBuildings2024-09-012025-08-3114284456core:PlantMachinery2024-09-012025-08-3114284456core:Vehicles2024-09-012025-08-3114284456core:FurnitureFittings2024-09-012025-08-3114284456core:OfficeEquipment2024-09-012025-08-3114284456core:NetGoodwill2024-09-012025-08-3114284456core:IntangibleAssetsOtherThanGoodwill2024-09-012025-08-3114284456core:ListedExchangeTraded2024-09-012025-08-3114284456core:UnlistedNon-exchangeTraded2024-09-012025-08-3114284456core:MoreThanFiveYears2024-09-012025-08-3114284456core:Non-currentFinancialInstruments2025-08-3114284456core:Non-currentFinancialInstruments2024-08-3114284456dpl:CostSales2024-09-012025-08-3114284456dpl:DistributionCosts2024-09-012025-08-3114284456core:LandBuildings2024-09-012025-08-3114284456core:PlantMachinery2024-09-012025-08-3114284456core:Vehicles2024-09-012025-08-3114284456core:FurnitureFittings2024-09-012025-08-3114284456core:OfficeEquipment2024-09-012025-08-3114284456dpl:AdministrativeExpenses2024-09-012025-08-3114284456core:NetGoodwill2024-09-012025-08-3114284456core:IntangibleAssetsOtherThanGoodwill2024-09-012025-08-3114284456dpl:GroupUndertakings2024-09-012025-08-3114284456dpl:ParticipatingInterests2024-09-012025-08-3114284456dpl:GroupUndertakingscore:ListedExchangeTraded2024-09-012025-08-3114284456core:ListedExchangeTraded2024-09-012025-08-3114284456dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-09-012025-08-3114284456core:UnlistedNon-exchangeTraded2024-09-012025-08-3114284456dpl:CostSales2023-09-012024-08-3114284456dpl:DistributionCosts2023-09-012024-08-3114284456core:LandBuildings2023-09-012024-08-3114284456core:PlantMachinery2023-09-012024-08-3114284456core:Vehicles2023-09-012024-08-3114284456core:FurnitureFittings2023-09-012024-08-3114284456core:OfficeEquipment2023-09-012024-08-3114284456dpl:AdministrativeExpenses2023-09-012024-08-3114284456core:NetGoodwill2023-09-012024-08-3114284456core:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3114284456dpl:GroupUndertakings2023-09-012024-08-3114284456dpl:ParticipatingInterests2023-09-012024-08-3114284456dpl:GroupUndertakingscore:ListedExchangeTraded2023-09-012024-08-3114284456core:ListedExchangeTraded2023-09-012024-08-3114284456dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-09-012024-08-3114284456core:UnlistedNon-exchangeTraded2023-09-012024-08-3114284456core:NetGoodwill2025-08-3114284456core:IntangibleAssetsOtherThanGoodwill2025-08-3114284456core:LandBuildings2025-08-3114284456core:PlantMachinery2025-08-3114284456core:Vehicles2025-08-3114284456core:FurnitureFittings2025-08-3114284456core:OfficeEquipment2025-08-3114284456core:AfterOneYear2025-08-3114284456core:WithinOneYear2025-08-3114284456core:ListedExchangeTraded2025-08-3114284456core:UnlistedNon-exchangeTraded2025-08-3114284456core:ShareCapital2025-08-3114284456core:SharePremium2025-08-3114284456core:RevaluationReserve2025-08-3114284456core:OtherReservesSubtotal2025-08-3114284456core:RetainedEarningsAccumulatedLosses2025-08-3114284456core:NetGoodwill2024-08-3114284456core:IntangibleAssetsOtherThanGoodwill2024-08-3114284456core:LandBuildings2024-08-3114284456core:PlantMachinery2024-08-3114284456core:Vehicles2024-08-3114284456core:FurnitureFittings2024-08-3114284456core:OfficeEquipment2024-08-3114284456core:AfterOneYear2024-08-3114284456core:WithinOneYear2024-08-3114284456core:ListedExchangeTraded2024-08-3114284456core:UnlistedNon-exchangeTraded2024-08-3114284456core:ShareCapital2024-08-3114284456core:SharePremium2024-08-3114284456core:RevaluationReserve2024-08-3114284456core:OtherReservesSubtotal2024-08-3114284456core:RetainedEarningsAccumulatedLosses2024-08-3114284456core:NetGoodwill2023-08-3114284456core:IntangibleAssetsOtherThanGoodwill2023-08-3114284456core:LandBuildings2023-08-3114284456core:PlantMachinery2023-08-3114284456core:Vehicles2023-08-3114284456core:FurnitureFittings2023-08-3114284456core:OfficeEquipment2023-08-3114284456core:AfterOneYear2023-08-3114284456core:WithinOneYear2023-08-3114284456core:ListedExchangeTraded2023-08-3114284456core:UnlistedNon-exchangeTraded2023-08-3114284456core:ShareCapital2023-08-3114284456core:SharePremium2023-08-3114284456core:RevaluationReserve2023-08-3114284456core:OtherReservesSubtotal2023-08-3114284456core:RetainedEarningsAccumulatedLosses2023-08-3114284456core:AfterOneYear2024-09-012025-08-3114284456core:WithinOneYear2024-09-012025-08-3114284456core:Non-currentFinancialInstrumentscore:CostValuation2024-09-012025-08-3114284456core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-09-012025-08-3114284456core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-09-012025-08-3114284456core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-09-012025-08-3114284456core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-09-012025-08-3114284456core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-09-012025-08-3114284456core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-09-012025-08-3114284456core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-09-012025-08-3114284456core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-09-012025-08-3114284456core:Non-currentFinancialInstrumentscore:CostValuation2025-08-3114284456core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-08-3114284456core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-08-3114284456core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-08-3114284456core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-08-3114284456core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-08-3114284456core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-08-3114284456core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-08-3114284456core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-08-3114284456core:Non-currentFinancialInstrumentscore:CostValuation2024-08-3114284456core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-08-3114284456core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-08-3114284456core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-08-3114284456core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-08-3114284456core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-08-3114284456core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-08-3114284456core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-08-3114284456core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-08-3114284456bus:Director12024-09-012025-08-31

Molecule Pharma Limited

Registered Number
14284456
(England and Wales)

Unaudited Financial Statements for the Year ended
31 August 2025

Molecule Pharma Limited
Company Information
for the year from 1 September 2024 to 31 August 2025

Director

Pranav Pradipkumar Shah

Registered Address

231 Kenton Road
Harrow
HA3 0HD

Registered Number

14284456 (England and Wales)
Molecule Pharma Limited
Statement of Financial Position
31 August 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Intangible assets31,474,1881,435,500
1,474,1881,435,500
Current assets
Debtors41,468104,212
Cash at bank and on hand104,318188,742
105,786292,954
Creditors amounts falling due within one year5(217,977)(98,098)
Net current assets (liabilities)(112,191)194,856
Total assets less current liabilities1,361,9971,630,356
Creditors amounts falling due after one year6(1,813,760)(1,655,147)
Net assets(451,763)(24,791)
Capital and reserves
Called up share capital81,16381,000
Profit and loss account(532,926)(105,791)
Shareholders' funds(451,763)(24,791)
The financial statements were approved and authorised for issue by the Director on 31 August 2026, and are signed on its behalf by:
Pranav Pradipkumar Shah
Director
Registered Company No. 14284456
Molecule Pharma Limited
Notes to the Financial Statements
for the year ended 31 August 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Going concern
The directors believe that the company is experiencing good levels of sales growth and profitability, and that it is well placed to manage its business risks successfully. Accordingly, they have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the financial statements.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Intangible assets
Intangible assets are stated at cost less accumulated amortisation and accumulated impairment losses. The assets are reviewed for impairment if the above factors indicate that the carrying amount may be impaired. Amortisation is included in 'administrative expenses' in the profit and loss account.
2.Average number of employees

20252024
Average number of employees during the year12
3.Intangible assets

Other

Total

££
Cost or valuation
At 01 September 241,650,0001,650,000
Additions150,000150,000
At 31 August 251,800,0001,800,000
Amortisation and impairment
At 01 September 24214,500214,500
Charge for year111,312111,312
At 31 August 25325,812325,812
Net book value
At 31 August 251,474,1881,474,188
At 31 August 241,435,5001,435,500
4.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables-93,990
Other debtors1,0001,000
Prepayments and accrued income4689,222
Total1,468104,212
5.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables200,7313,720
Taxation and social security14,95192,628
Accrued liabilities and deferred income2,2951,750
Total217,97798,098
6.Creditors: amounts due after one year

2025

2024

££
Other creditors1,813,7601,655,147
Total1,813,7601,655,147